This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/chemspider/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/chebi/
n16http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/wikipedia/
n11http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/kegg-compound/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00827/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00827
rdf:type
n3:Drug
n3:description
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. [PubChem]
n3:group
approved withdrawn
n3:halfLife
The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours.
n3:indication
For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Proteus vulgaris</i>, <i>Klebsiella</i> species (including <i>K. pneumoniae</i>), and <i>Enterobacter</i> species.
n3:manufacturer
n12:271B4721-363D-11E5-9242-09173F13E4C5 n12:271B4722-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00827 n16:DB00827
dcterms:title
Cinoxacin
adms:identifier
n15:Cinoxacin n17:2762 n18:46507547 n19:D00872 n20:PA449007 n21:DB00827 n22:C08052 n23:3716 n24:2660
n3:mechanismOfAction
Evidence exists that cinoxacin binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. It appears to also inhibit DNA gyrase. This enzyme is necessary for proper replicated DNA separation. By inhibiting this enzyme, DNA replication and cell division is inhibited.
n3:synonym
Cinoxacino Cinoxacin 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid Cinoxacinum Cinoxacine 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
n3:toxicity
Oral, subcutaneous, and intravenous LD<sub>50</sub> in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD<sub>50</sub> in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively.Symptoms following an overdose of cinoxacin may include anorexia, nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have been reported in some patients.
n3:proteinBinding
60 to 80%
n3:synthesisReference
White, W.A.; U.S. Patent 3,669,965; June 13, 1972; assigned to Eli Lilly & Company.
foaf:page
n6:cinobac.htm n11:cinoxacin.html
n3:IUPAC-Name
n4:271B4727-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B472D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B472C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4729-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B472A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B472B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4725-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4723-363D-11E5-9242-09173F13E4C5 n4:271B4726-363D-11E5-9242-09173F13E4C5 n4:271B473E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4724-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:J01MB06
n3:H-Bond-Acceptor-Count
n4:271B4733-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4734-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B472E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B472F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4731-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4730-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4732-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed after oral administration. The presence of food delays absorption but does does not affect total absorption.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
28657-80-9
n3:Bioavailability
n4:271B4739-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B473B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B473C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B473D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4738-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4737-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B473A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4728-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4735-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4736-363D-11E5-9242-09173F13E4C5